Jim Cramer details what the rotation out of growth and into value means for the bull market. » Read More
By: Elizabeth Gurdus
Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis. » Read More |
As the cannabis industry grows in other parts of the world, Amsterdam finds itself playing catch-up. » Read More |
By: Thomas Franck
Wall Street's obsession with marijuana stocks has propelled industry leaders to lofty market valuations. Canadian cannabis company Tilray is now larger than 45 percent of the stocks that comprise the S&P 500. » Read More |
Five trading halts, a surge of 90% and all of its shares changing hands... all in a day's work for volatile pot stock Tilray.
Jim Cramer explains how China's manufacturing-based economy leaves it vulnerable to U.S. trade tariffs.
Jim Cramer sits down with Tilray CEO Brendan Kennedy to get his take on the future of medical and recreational marijuana.
Jim Cramer reveals the big opportunity behind the decline in medical device stocks.
It seems like an implausible solution: Accepting a transplant of an organ that is infected with hepatitis C. But, some patients faced with a last resort are doing just that -- accepting infected organs and then starting a course of antiviral drugs to eliminate traces of the virus, USA Today reports.
President Donald Trump urges Senate to pass legislation that would prohibit "gag clauses," which prevent pharmacists from telling patients paying with cash may be less expensive than using their insurance benefits.
Scientists are making progress on lab-grown meat – meat that's grown by putting a live animal's stem cells in nutrient-rich liquid – but consumers may not be ready for it, these research scientists explain in The Conversation.
"The evidence is mounting, both in our company and outside, that you can intervene and you can change the course of these specific diseases," says Unity Biotechnology CEO Keith Leonard.
Pain can be debilitating and also challenging to treat, especially as opioids have come under scrutiny for their role in fueling a nationwide epidemic.
Nirmal Mulye, founder of Nostrum Pharmaceuticals, argues the generic drug business has become so bogged down in inefficiencies at the Food and Drug Administration, his business lost money in eight of the past 11 years.
Advocates for opioid overdose drugs in elementary schools argue that "whatever is going on in our country will be in our schools," and waiting until a child dies is waiting too long, USA Today reports.
The CDC estimates that more than 700,000 people were hospitalized with the flu during last season with epidemic levels of influenza or pneumonia for 16 consecutive weeks. Some 180 children died from the most recent bout of flu.
While most medical schools now offer some education about opioids, only about 15 of 180 American programs teach addiction including alcohol, tobacco and other drugs, The New York Times reports.
Sarepta Therapeutics CEO Doug Ingram wants the company to start giving its Duchenne muscular dystrophy gene therapy to children in the approval trial by the end of this year and to the community two years after that.
The Auvi-Q's introduction to Walgreens comes as manufacturing disruptions have led to an EpiPen shortage. Drugstores across the country have no or very few EpiPens in stock.
The initial focus of the venture, known as Civica Rx, will be a group of 14 generic drugs that are administered to patients in the hospital.
Get the best of CNBC in your inbox
Data also provided by 
